# Tesamorelin FAQ: Mechanism, IGF-1, Fat Loss, Safety, and Status | Tesamorelin

> Tesamorelin FAQ: how it works, whether it raises IGF-1, fat-loss timelines, liver fat, blood sugar, FDA-approval scope, what happens when you stop, and safety. Direct, cited answers.

Direct answers to the most common questions about tesamorelin's mechanism, effects, safety, and regulatory status — each cited to the published literature.

## What is tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analogue of growth hormone-releasing hormone (GHRH(1-44)) with an N-terminal trans-3-hexenoyl group that resists DPP-IV cleavage [4]. It stimulates the body's own growth hormone and raises IGF-1 [11], and it is FDA-approved only for HIV-associated lipodystrophy [5].

## What does tesamorelin do?

By stimulating pulsatile growth hormone and IGF-1, tesamorelin promotes lipolysis preferentially in visceral abdominal fat [1]. In HIV-associated lipodystrophy trials it selectively reduced visceral fat without significant change in subcutaneous fat or BMI [1][2].

## How does tesamorelin work?

Tesamorelin binds the GHRH receptor on pituitary somatotrophs, activating the Gs/cAMP/PKA cascade to stimulate synthesis and pulsatile secretion of the body's own growth hormone [11]. That growth hormone raises liver-produced IGF-1 and, together with it, promotes visceral-fat lipolysis [1]. It amplifies the body's natural GH rhythm rather than supplying hormone directly [6].

## Is tesamorelin a growth hormone?

No. Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue. It prompts the pituitary to make and release its own growth hormone rather than supplying growth hormone directly, so it amplifies the body's natural pulsatile rhythm [11]. This upstream action is what distinguishes a secretagogue from recombinant growth hormone [6].

## Does tesamorelin raise IGF-1 levels?

Yes. In 13 healthy men, tesamorelin 2 mg/day for two weeks raised IGF-1 by 181 ug/L [4]; the pivotal HIV trial reported an 81% IGF-1 increase [1]; and in obese adults with reduced GH the IGF-1 rise tracked with improved muscle phosphocreatine recovery [7]. Raising IGF-1 is a consistent, reproducible effect across these populations.

## How does tesamorelin stimulate growth hormone release?

It activates the GHRH receptor on pituitary somatotrophs (a Gs-coupled receptor), raising intracellular cAMP and driving both GH-gene transcription and granule exocytosis, so growth hormone is released in the body's natural episodic bursts. PK-PD modeling confirmed this episodic, exposure-linked GH secretion [11].

## Does tesamorelin increase testosterone?

Tesamorelin acts on the growth hormone / IGF-1 axis, not the gonadal axis; the trials measured GH and IGF-1 increases, and there is no controlled evidence in this literature that tesamorelin raises testosterone. Sex steroids do modulate GHRH-driven GH output [8][10], but that is the reverse direction of effect.

## Will tesamorelin help me lose belly fat?

The controlled fat-loss evidence is in HIV-associated lipodystrophy, where tesamorelin 2 mg/day reduced visceral abdominal fat by roughly 15-18% [1][2]. No large general-population fat-loss randomized trial has been completed, so non-HIV use is off-label and unproven [5]. This site describes findings, not a course of use.

## How long does it take to see fat loss from tesamorelin?

In the pivotal trials, visceral-fat reduction was measured at 26 weeks and sustained through 52 weeks of continued dosing [1][2]. The effect depended on ongoing treatment in the studied HIV population, and reaccumulation followed discontinuation [2].

## Does tesamorelin burn belly fat?

In the studied HIV-lipodystrophy population it selectively reduced visceral (intra-abdominal) fat via GH/IGF-1-driven lipolysis [1]. A 2026 meta-analysis of five randomized trials put the pooled visceral-fat reduction at about -27.7 cm2 [15]. Subcutaneous fat and BMI were largely unchanged [1].

## Does tesamorelin increase the risk of diabetes or affect blood sugar?

In 13 healthy men, two weeks of tesamorelin left fasting glucose and insulin-stimulated glucose uptake unchanged [4], and across the 52-week HIV program glucose changes were not clinically significant [2]. Modest glucose perturbation can occur as a growth-hormone-class effect, so monitoring is reasonable in dysglycemia.

## Does tesamorelin work for fat loss in non-HIV users?

The pivotal efficacy trials enrolled HIV-positive adults on antiretroviral therapy [1][2]. Generalizing to non-HIV populations is mechanistically plausible but not established by large randomized trials; non-HIV fat-loss use is off-label [5].

## Is tesamorelin a potential treatment for non-alcoholic fatty liver disease?

In HIV patients, tesamorelin reduced hepatic fat in a JAMA trial (net -2.9% liver lipid, P=0.003) [3], and a 2026 meta-analysis pooled a -4.28% hepatic-fat-fraction reduction across five trials [15]. It is studied as an off-label research endpoint; the authors noted further work is needed on liver histology.

## How does tesamorelin affect the liver in NAFLD?

It lowers hepatic fat alongside visceral-fat reduction; a 2026 meta-analysis reported a pooled hepatic-fat-fraction reduction of about -4.28% [15]. The proposed mechanism is GH/IGF-1-driven lipolysis acting on intra-abdominal fat, the studied mediator of the metabolic benefit [12].

## Can tesamorelin reduce liver fat?

Yes, in the studied HIV populations: the JAMA 2014 trial showed a net -2.9% hepatic lipid reduction (P=0.003) [3], and the 2026 meta-analysis pooled a -4.28% hepatic-fat-fraction reduction across five trials [15]. Outside HIV populations this remains an off-label research question.

## What is the half-life of tesamorelin?

Plasma exposure is short. Population PK modeling reported apparent clearance around 1,060 L/h [11]; secondary sources describe a terminal half-life on the order of 26-38 minutes. Despite rapid clearance, IGF-1 stays elevated across the day, supporting once-daily dosing [11].

## How long does tesamorelin stay in your system?

Tesamorelin itself clears the plasma quickly (terminal half-life roughly 26-38 minutes per secondary sources), but its downstream effect on IGF-1 persists across the dosing interval, which is why studies used once-daily administration [11].

## What are the side effects of tesamorelin?

Trial-reported effects centered on growth-hormone-class effects, with monitoring of glucose and serum IGF-1 [1][2]; long-term oncologic-safety data are limited and active malignancy is a contraindication [5]. NIH LiverTox rates tesamorelin class E, unlikely to cause clinically apparent liver injury [5].

## Does tesamorelin cause water retention?

Fluid-related effects are a recognized growth-hormone-class phenomenon tied to GH-axis stimulation. Across the 52-week HIV program the clinically meaningful glucose changes were absent, and the principal safety signals were class effects of raising endogenous GH and IGF-1 [2].

## Who should not take tesamorelin / who should avoid it?

Because tesamorelin raises IGF-1, active malignancy is a contraindication in the research literature, and long-term oncologic-safety data remain limited [5]. It is also a WADA-prohibited substance (category S2), barred in competitive sport. Research-grade material is supplied for laboratory use only, not human self-administration.

## Is tesamorelin FDA approved?

Yes, but narrowly: tesamorelin was FDA-approved in 2010 (NDA 022505) to reduce excess abdominal visceral fat in HIV-infected adults with lipodystrophy [5]. It has no FDA-approved use outside that indication; all other uses are off-label.

## What happens when you stop taking tesamorelin? Does the fat come back?

In the 52-week program, visceral fat reaccumulated after discontinuation, indicating the benefit was contingent on continued dosing in the studied population [2]. The effect behaved as a maintained state rather than a permanent change.

---

The tesamorelin literature read as one procession of banner-marked findings -- the visceral-fat and IGF-1 trials carried back to their studies, the FDA-approved HIV-lipodystrophy scope held in the gold and every off-label use kept off-label, the reverts-when-you-stop and IGF-1 caveats flying their own pennants; an ornamented digest of the published evidence, never a clinic, a vendor, or a prescription.